|Print Page Close Window|
BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival...more >
BGNE (American Depositary Shares)
12/14/17 4:00 p.m. ET
Currency is USD
There are currently no events scheduled.
Sign up to receive e-mail alerts
© 2016 BeiGene. All Rights Reserved.